

**REMARKS**

Claims 1-58 are currently pending in this application. Claims 23, 25, and 51 are amended to correct minor grammatical errors. No claims are added or canceled.

The Examiner has required restriction between one of the following inventions as required under 35 U.S.C. 121:

Group I: Claims 1-8, 10-19, 26-36, 41-45, 50-53, 56 and 57, drawn to methods of identifying therapeutic compounds, classified in class 205, subclass 775; and

Group II: Claims 9, 20-25, 37-40, 46-49, 54, 55, and 58, drawn to therapeutic compounds, classified in class 424, subclass 9.2.

Applicants hereby elect Group I, Claims 1-8, 10-19, 26-36, 41-45, 50-53, 56 and 57 for examination on the merits. Election is made without traverse.

The Examiner has further required election of species among the following species:

(Species A) oxidative stress (claims 9-40 and 50-58); and

(Species B) amyloid- $\beta$  fibril formation (claims 41-49).

Applicants hereby elect Species A, oxidative stress, claims 9-40 and 50-58. Claims 1-8, 10-19, 26-36, 50-53, 56, and 57 read on species A.

The Examiner has further required a subspecies election if Species A is elected, among the following subspecies:

(Species Aa) inflammation (claims 9-39 and 50-58);

(Species Ab) neurodegeneration (claims 9-28, 30, 31, 33-40, and 50-58); and

(Species Ac) ischemia (claims 9-28, 30, 31, 33-40, and 50-58).

Applicants hereby elect Species Ab, neurodegeneration, claims 9-28, 30, 31, 33-40, and 50-58.

Claims 1-8, 10-19, 26-28, 30, 31, 33-36, 50-53, 56, and 57 read on species Ab. (Claims 9, 20-25, 37-40, 54, 55, and 58 are to a non-elected invention.)


Applicants expressly reserve the right under 35 U.S.C. § 121 to file one or more divisional applications directed to the non-elected subject matter. Upon the allowance of a generic claim, Applicants respectfully request consideration of the additional species and subspecies in addition to the elected species and subspecies, as provided by 37 CFR 1.141.

Applicants respectfully request examination on the merits.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 526302000400. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 26, 2007

Respectfully submitted,

By   
Robert K. Cerpa  
Registration No.: 39,933  
MORRISON & FOERSTER LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
(650) 813-5715